Phase II trial of lenvatinib (LEN) at two starting doses + everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).Sumanta K. Pal, Sun Young Rha, P. Koralewski et al.|Journal of Clinical Oncology|2021Cited by 11
Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.Cristiane Decat Bergerot, Javier Puente, Sun Young Rha et al.|Journal of Clinical Oncology|2021Cited by 1